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Abstract
Background Facioscapulohumeral muscular dystrophy (FSHD) is one of the most frequent late-onset muscular dystrophies,
characterized by progressive fatty replacement and degeneration involving single muscles in an asynchronous manner. With
clinical trials at the horizon in this disease, the knowledge of its natural history is of paramount importance to understand
the impact of new therapies. The aim of this study was to assess disease progression in FSHD using qualitative muscle mag-
netic resonance imaging, with a focus on the evolution of hyperintense lesions identified on short-tau inversion recovery
(STIR+) sequences, hypothesized to be markers of active muscle injury.
Methods One hundred genetically confirmed consecutive FSHD patients underwent lower limb muscle magnetic resonance
imaging at baseline and after 365 ± 60 days in this prospective longitudinal study. T1 weighted (T1w) and STIR sequences were
used to assess fatty replacement using a semiquantitative visual score and muscle oedema. The baseline and follow-up scans
of each patient were also evaluated by unblinded direct comparison to detect the changes not captured by the scoring system.
Results Forty-nine patients showed progression on T1w sequences after 1 year, and 30 patients showed at least one new
STIR+ lesion. Increased fat deposition at follow-up was observed in 13.9% STIR+ and in only 0.21% STIR- muscles at baseline
(P < 0.001). Overall, 89.9% of the muscles that showed increased fatty replacement were STIR+ at baseline and 7.8% were
STIR+ at 12 months. A higher number of STIR+ muscles at baseline was associated with radiological worsening (odds ratio
1.17, 95% confidence interval 1.06–1.30, P = 0.003).
Conclusions Our study confirms that STIR+ lesions represent prognostic biomarkers in FSHD and contributes to delineate its
radiological natural history, providing useful information for clinical trial design. Given the peculiar muscle-by-muscle involve-
ment in FSHD, MRI represents an invaluable tool to explore the modalities and rate of disease progression.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD), the second
most prevalent muscular dystrophy with onset in adulthood,1
is a slowly progressing disorder characterized by a
heterogeneous and often asymmetric muscle involvement,
usually starting form facial and scapular fixator muscles and
later spreading to upper arms, trunk, and lower limbs.2 The
clinical spectrum of the disease is wide, ranging from asymp-
tomatic or minimally disabled patients to severe wheelchair
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bound subjects.3 In its most frequent form (FSHD1), it is
inherited as an autosomal dominant trait associated with a
contraction of the D4Z4 macrosatellite repeat array on the
4q chromosome which, together with a permissive haplotype
distal to the last of these repeats, allows the inappropriate
expression of the DUX4 retrogene in adult skeletal muscle.4
Significant efforts have been made to develop therapies
that could potentially counteract this disease, for example,
preventing or slowing the loss of muscle mass, and promising
approaches are emerging.5,6 To evaluate the efficacy of such
treatments, the research community is committed to identify
biomarkers and develop outcome measures for clinical trial
purposes.7
In the last years, the increasingly widespread use of stan-
dard and quantitative muscle magnetic resonance imaging
(MRI) in FSHD patients suggested a non-linear model of dis-
ease progression that proceeds with a muscle-by-muscle type
of involvement,8 in which an early phase of muscle damage,
identifiable by increased signal on short-tau inversion recov-
ery (STIR) sequences accounting for oedema/inflammation,
precedes fatty replacement of single muscles.9–12 This would
be consistent with the proposed model of disease pathophys-
iology, according to which bursts of inappropriate expression
of the DUX4 retrogene, normally repressed in adult striated
skeletal muscle, lead to a cascade of downstream events,
not yet fully understood but potentially inclusive of an inflam-
matory-immune response,13–16 that in the end generate
skeletal muscle wasting.17 In this context, STIR positive
(STIR+) muscle lesions have been proposed as biomarkers of
disease activity. Therefore, large studies to confirm that
STIR+ lesions can be reliably correlated with phases of disease
activity at single muscle level are primarily expected by the
FSHD research community, but missing so far.18
Recent longitudinal imaging studies indeed focused on
quantitative evaluation of fatty replacement and its correla-
tion with clinical measures of disease progression, providing
only limited information on the rate of appearance and evo-
lution of STIR+ lesions.19–21
To contribute to answer these relevant questions, we de-
signed this longitudinal study using conventional muscle
MRI with the following aims: (i) to determine the evolution
of STIR+ lesions after 1 year time, in comparison with the evo-
lution STIR- muscles; (ii) to assess the rate of appearance of
new STIR+ lesions in the same time frame; (iii) to determine
how often fatty replacement is preceded by a STIR+ lesion de-
tectable 1 year earlier.
Patients and methods
Patients
All FSHD patients routinely followed up at the Fondazione
Policlinico Universitario A. Gemelli IRCCS were asked to
participate to this prospective longitudinal study that took
place between January 2014 and December 2017. The target
of enrolment was 100 consecutive patients. Among the en-
rolled patients, 74 were also involved in our previous large
cross-sectional MRI study.8 Inclusion and exclusion criteria
were identical to that previous study and were designed to
include only adult, genetically proven, symptomatic FSHD1
patients. Disease severity was evaluated with the clinical se-
verity scale (CSS),22 ranging from asymptomatic patients
(score = 0) to patients who lost ambulation (score = 5). At
the time of clinical examination, patients were asked to un-
dergo a baseline (within 2 weeks) and a follow-up scan at 1
year distance (365 ± 60 days).
Magnetic resonance imaging protocol and
evaluation
Lower limb muscle MRI scans were performed at a single cen-
tre using a 1.5T commercial scanner (Siemens Magnetom
Espree, Erlangen, Germany). T1 weighted (T1w) and STIR se-
quences were acquired using published protocols.8
One neurologist expert in muscle imaging (M. M.) and one
MD student trained in muscle imaging (M. B.) independently
assessed all the scans. Baseline and follow-up images were
first evaluated using a 5-point semiquantitative scale to as-
sess the extent of fatty replacement in single muscles on
T1w sequences23 and using a binary score (i.e. yes or no) to
judge the presence of hyperintensities on STIR sequences. A
total of 35 muscles were assessed on each side throughout
their length. Subsequently, to detect more subtle changes
not identified by the former assessment, the observers per-
formed a direct visual comparison between the baseline
and the follow-up scan of each patient on the same computer
monitor. After careful alignment, using bony landmarks (fem-
oral head and tibial plateau) as reference, the observers clas-
sified every muscle into one of the 16 categories summarizing
all the possible combinations of evolution on T1w and STIR
sequences (Table 1). Radiological worsening in single muscles
was defined as an increase in fatty replacement or evident
decrease in size and/or an appearance of a new hyperintensity
on STIR sequences, as defined in the categories 4–6, 8–12, 14,
and 15 of Table 1. Time needed to perform the scoring of one
scan was 25 min; time needed to perform one comparison
was 35min on average.
Statistical analysis
Data are expressed as mean ± standard deviation unless oth-
erwise specified and were analyzed using IBM SPSS Statistics
ver. 22. All P-values <0.05 were considered statistically signif-
icant. Shapiro–Wilk test was used to assess data distribution,
and each time, the appropriate statistic was chosen
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accordingly. T1 score was calculated as the sum of the scores
of involvement of the individual muscles in each patient, using
the 5-point scale for fatty replacement. Independent sample t-
test was used to evaluate differences regarding age, EcoRI
fragment length, CSS, baseline T1 score, and number of STIR
+ muscles. Paired t-test was used to ascertain differences in
T1 score and number of STIR+ muscles between baseline and
follow-up scans; χ2 test was used to assess differences be-
tween the number of STIR+ and STIR- muscles with increased
fatty replacement at follow-up. Cohen’s κ was used to deter-
mine if there was agreement between the two raters on the
classification system adopted for this project. A logistic regres-
sion was performed to ascertain the effects of age, gender,
EcoRI fragment length, CSS, T1 score, and number of STIR+
muscles at baseline on the likelihood that the patients
displayed radiological progression in at least one muscle.
Results
Patients and baseline results
Baseline MRI scans were acquired in the period January
2014–December 2016. Forty-nine men and 51 women were
enrolled. Mean age at baseline was 44.45 ± 13.99 years
(range 18–71), mean EcoRI fragment length was 24.18 ±
5.62 kb (range 10–38), and median CSS was 3.0 (interquartile
range 1.8, range 0.5–4.5).
All the patients except one, whose CSS was 0.5, showed
lower limb involvement on MRI at baseline. Mean number
of muscles affected on T1w sequences was 32.56 ± 19.59
(range 0–68) per patient. Mean T1 score was 71.9 ± 50.79
(range 0–183). Eighty-four patients had at least one STIR+
muscle. Mean number of STIR+ muscles per patient was
Table 1 Classification system used to identify the differences between baseline and follow-up MRI scans and results of the comparisons
STIR, STIR sequences; T1, T1w sequences; -, unaffected; +, affected; ++, worsening of an already affected muscle. An evident change in
the size of the muscle (hypotrophy) was also considered as worsening. White background: muscle showing no changes from baseline to
follow-up MRI; red background: muscle displaying changes (i.e. radiological worsening); and green background: muscle with STIR+ le-
sions only at baseline without progression on T1w sequences.
Longitudinal qualitative muscle MRI in FSHD 3
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12473
8.27 ± 6.77 (range 0–33), and the total number of STIR+ mus-
cles was 827 (11.8% of the total).
We found no differences comparing male and female
groups with respect to age, CSS, and T1 score while a
statistically significant difference in EcoRI fragment length
(men 25.98 ± 5.8 kb, women 22.45 ± 4.9 kb, P = 0.001) and
number of STIR+ muscles (men 10.39 ± 6.85, women 6.24 ±
6.09, P = 0.002) was observed. A summary of clinical, genetic,
and radiological features is reported in Supporting Information,
Table S1.
Follow-up scans
The observers agreed in classifying muscles in one of the 16
categories in 93% of cases, and in the remaining 7%, consen-
sus was reached by consultation. There was substantial
agreement between the two raters’ judgements, with κ =
0.861 (95% confidence interval 0.841–0.878, P < 0.001).
Mean T1 score at follow-up was higher than baseline
(72.28 ± 50.92, range 0–184, P < 0.001). Twenty-three pa-
tients showed increased T1 score at follow-up, while no pa-
tient showed a decrease. The direct comparison of the
scans allowed to detect an increase in fat deposition in at
least one muscle in 26 additional patients. Overall, 49
patients (25 men and 24 women) showed detectable changes
on T1w sequences after 1 year.
The majority of the muscles (n = 6813, 97.3% of the to-
tal, categories 0–3, Table 1) did not show changes at fol-
low-up; an increase of at least one point in the
semiquantitative score was found in 0.53% of the muscles
(n = 37), while the direct comparison showed an increase
in fat content in 1.83% (n = 128; categories 5, 6, 8, 9, 11, 12,
14, and 15, Table 1). Themuscles that more frequently showed
progression on T1w images were the gracilis (n = 14),
gastrocnemius medialis (n = 14), and tibialis anterior (n = 10)
(Supporting Information, Figure S1). This progression consisted
inmuscle hypotrophy rather than increase of fatty replacement
in aminority of cases andonly for somemuscles thatwere STIR+
atbaseline: tibialis anterior (4outof8 cases), gracilis (5outof12
cases), and sartorius (3 out of 8 cases). Examples of different
typesofprogressionare shown inFigure1. Thecomplete scoring
data set is available as Supporting Information, Table S2.
No significant difference was found in the number of STIR+
muscles at follow-up (8.45 ± 6.76, range 0–33) compared with
baseline evaluation. A new STIR+ lesion was displayed by
0.73% of the muscles at follow-up (n = 51, 25 with a score 0,
21with a score 1–2, 5with a score 3, and none with a score 4).
Thirty patients (18 men and 12 women, mean age 40.47 ±
15.6, median CSS 3.0 interquartile range 2.0, mean EcoRI
fragment length 24.5 ± 6.53 kb, mean T1 score at baseline
Figure 1 Different types of progression at 1 year in single muscles (baseline on the left-hand side and follow-up on the right of each panel). (A) Patient
41: worsening on T1w sequences with persistence of STIR hyperintensity in vastus lateralis (arrow) and medialis (asterisk); in the same patient, the STIR
+ sartorius (arrowhead) becomes atrophic and STIR- at follow-up; (B) Patient 35: a new hyperintense lesion in STIR sequences accompanied by volume
loss is evident in the tibialis anterior (arrowhead); (C) Patient 65: normalization of STIR signal without apparent changes on T1w images in the
semitendinosus (arrow); (D) Patient 63: right soleus (asterisk, STIR+ at baseline), left soleus (triangle), and right gastrocnemius medialis (arrowhead,
STIR+ at follow-up scan) becoming almost completely replaced by fat tissue after 1 year; appearance of a new STIR+ muscle (gastrocnemius lateralis,
arrow) with normal signal in T1w sequences. STIR, short-tau inversion recovery.
4 M. Monforte et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12473
69.2 ± 55.54) showed at least one muscle with a new STIR+
lesion.
Evolution of STIR+ muscles
Out of the 128 muscles that showed progression on T1w
images, 115 (89.9%) were STIR+ at baseline and 10 (7.8%)
were STIR+ at follow-up.
The majority of the STIR+ muscles at baseline (n = 694,
83.9%) showed no changes either on T1w or on STIR
sequences at follow-up while 13.9% (n = 115) worsened on
T1w sequences, thus displaying increased fatty replacement.
On the contrary, only 0.21% of the STIR- muscles at baseline
(n = 13) showed progression on T1w images at follow-up. In
2.2% of the STIR+ muscles (n = 18, corresponding to 11
patients, 6 men and 5 women), a normalization of STIR signal
without detectable changes on T1w sequences was observed
(Figure 2). The difference between STIR+ and STIR- muscles in
the progression to fatty replacement at follow-up was
statistically significant (P < 0.001). Higher values of T1 score
(94.94 ± 41.58 vs. 55.77 ± 48.57, P < 0.001) and CSS (median
3.5 interquartile range 1.0 vs. median 3.0 interquartile range
2.0, P< 0.001) were found in patients (n = 48, 25men and 23
women) who had at least one STIR+ muscle that progressed
on T1w sequences, compared with patients (n = 35, 21 men
and 14 women) who had only STIR+ muscles that did not
show increase in fatty replacement.
Determinants of radiological worsening
Radiological worsening in at least one muscle, as previously
defined, occurred in 59 patients (31 men and 28 women).
The logistic regression model built to ascertain the effects
of age, gender, EcoRI fragment length, CSS, T1 score, and
Figure 2 Evolution of STIR+ muscles at baseline. Patients (left to right) 80, 40, 9, 5, and 24. T1, T1w sequences; -, unaffected; +, affected; ++, wors-
ening; =, no changes. STIR, short-tau inversion recovery.
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number of STIR+ muscles at baseline on the likelihood of
displaying radiological worsening in at least one muscle was
statistically significant, χ2(6) = 29.89, P < 0.001. The model
explained 34.8% (Nagelkerke R2) of the variance and cor-
rectly classified 76% of cases. Among all these variables,
only an increase in the number of STIR+muscleswas associated
with a higher likelihood of radiological worsening at follow-up
(odds ratio 1.17, 95%confidence interval 1.06–1.30, P = 0.003).
Discussion
Several cross-sectional imaging studies reported the most fre-
quent patterns of involvement in FSHD,8,24,25 but only scarce
longitudinal data are present in the literature, mostly focused
on quantitative evaluation of fatty replacement and its corre-
lation with clinical measures of disease progression with no
or limited information on the rate of appearance and evolution
of STIR+ lesions.19–21 In this study, we performed a longitudi-
nal follow-up of a large cohort of FSHD patients by lower limb
muscle MRI. Lower limbMRI was chosen because more widely
available and for the higher likelihood of finding STIR+ lesions
compared with upper girdle imaging.8 In a heterogeneous
and slowly progressive disease such as FSHD, conventional
MRI examination was able to detect signs of progression in
terms of fatty replacement in almost half of the studied pa-
tients after 1 year. The direct comparison of the baseline and
follow-up scans identified an increase of fat accumulation with
higher sensitivity than the 5-point semiquantitative evalua-
tion. Other limited natural history data on FSHD are available:
a clinical study that followed patients over 36months showed
a slight decline in a mean voluntary isometric contraction test
after 12months and of an averaged composite manual muscle
testing score after 18 months, but no predictors of disease
progression were identified in that study.26 Quantitative MRI
demonstrated that fat fraction progressed in different muscles
on average by 3.6% per year,19 without differential evaluation
of STIR+ and STIR- muscles. Clinical tools to more accurately
identify disease progression are currently under development;
muscle imaging depicts different and complementary aspects
of disease progression, and the integration of the two assess-
ments could be the best way to define reliable, sensitive, and
meaningful outcome measures.
The results provided with the present study are relevant
for the upcoming clinical trials in FSHD for different reasons:
(i) enrolling patients with STIR+ muscles, thus more prone
to show disease progression in a short time frame, would
maximize the chances to detect a meaningful effect of an
investigational treatment; (ii) slowing down the evolution of
STIR+ lesions towards fatty replacement, increasing the rate
of disappearance of STIR+ lesions, or lowering the occurrence
of new STIR hyperintensities could be considered proof of
efficacy of the treatment.
We indeed found that STIR+ muscles progress faster
towards fatty replacement: after 1 year, almost 14% of the
STIR+ muscles showed signs of increased fat amount, while
only 0.2% of STIR- muscles demonstrated such an evolu-
tion. The evidence that a higher number of STIR+ muscles
at baseline predicts worsening at follow-up further supports
the link between STIR+ lesions and disease progression.
Similarly, we found that the increase in fatty replacement
at single muscle level is almost invariably preceded by a
phase characterized by the presence of STIR+ lesions de-
tectable 12 months before. Our results thus confirm that
STIR hyperintense lesions are prognostic biomarkers as they
can identify an active phase of the disease with faster pro-
gression towards muscle destruction. We cannot rule out
the possibility that even all the evolutions towards fat
replacement are preceded by a phase of STIR positivity,
which would be virtually impossible to prove. This is how-
ever further suggested by the fact that most of the STIR-
muscles at baseline that increase in fat content show STIR
positivity at follow-up.
The link between STIR+ lesions and disease progression
had already been suggested by smaller studies: Friedman et
al. found that STIR+ muscles evolved to fatty replacement
in 3 out of 9 patients followed by MRI of the calves over 2
years, while no evolution was seen in STIR- muscles.11 At var-
iance, one recent study by the same group on a cohort of 15
patients followed for 1 year found that only 4 out of 7 mus-
cles that progressed on T1w sequences were STIR+ at base-
line,27 partly questioning this proposed link. However, we
might hypothesize that the small number of patients exam-
ined, the heterogeneity of the disease, or even the different
MRI protocols and subjective evaluation of STIR images could
account for this discrepancy with our and previous studies.10
Here, we also confirmed earlier findings that women dis-
play STIR+ muscles less frequently than men,8,28 although
without a corresponding significant decrease in radiological
worsening over 1 year, thus suggesting that STIR+ lesions
are somehow more long lasting in men. This is in keeping
with the recent evidences of a proposed protective effect
of oestrogens by antagonizing DUX4 activity and at least
partially preventing the activation of the cascade of patho-
genic events downstream DUX4 transcription,29 while ac-
cording to recent clinical study, differences in endogen
oestrogen exposure during life did not seem to have a clin-
ically relevant modifying effect on disease severity in fe-
male patients.30 It also suggests that other sex-related
factors might play a role in the development or further pre-
vention of DUX4-mediated muscle damage as well.
It is known that STIR+ muscles are characterized by an
inflammatory component, whose role is not yet fully under-
stood. The fact that the majority of STIR hyperintensities
are rather long lasting (83.9% remained unchanged at 1
year) and that some of them may even normalize on MRI
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without macroscopic consequences on T1w images is in-
triguing. The implementation of quantitative MRI tech-
niques and pathology studies might clarify whether this
evolution corresponds to an accumulation of fat that is un-
der the sensitivity threshold of standard MRI or whether it
corresponds to deposition of fibrotic tissue, whose assess-
ment is a current limitation of all MRI techniques, but
can be for instance visualized by muscle ultrasound.31 The
molecular link between DUX4 activation and STIR positivity
has been evaluated by a recent study on MRI-targeted
muscle biopsies, finding that abnormal STIR signal is a reli-
able predictor of the presence of DUX4 target expression.32
Further studies aimed at clarifying if inflammation repre-
sents a protective attempt against the DUX4-driven delete-
rious effects or a direct detrimental component of the
DUX4 cascade are needed to understand more of the dis-
ease and for therapy development.
A limitation of the present study is that we did not mea-
sure the difference in longitudinal fatty replacement between
STIR+ and STIR- muscles with quantitative techniques for fat
or water content. It is known that semiquantitative imaging
scores globally correlate with the actual fat fraction, but a
wide range of fat fractions can exist within the same visual
grade, so quantitative imaging is definitely more precise in
measuring time differences in single muscles.33 Furthermore,
advanced MRI techniques allow to measure the water T2,
that is more accurate to muscle oedema changes compared
with STIR imaging.34,35 Our study is however complementary
to quantitative ones, providing different information by
allowing an extensive and fast evaluation of all the muscles
in the lower limbs along all their length. It also helps to in-
form longitudinal quantitative MRI studies to find suitable
targets and regions of interest to be effectively monitored
(or avoided) in a 1 year time frame.
In summary, in a slowly progressive disease such as FSHD,
where clinical assessment alone may fail to detect modifica-
tions of the natural history of the disease induced by treat-
ments in a relatively short time frame, having sensitive
prognostic biomarkers is extremely useful for clinical trial de-
sign, including correct patient stratification and evaluation of
treatment efficacy. Our work sheds light on the radiological
natural history of FSHD and further supports the role of this
technique in defining predictors of disease progression.
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